Merck KGaA replaces retiring R&D chief

15 October 2020

Germany’s Merck KGaA (MRK: DE) today announced that Dr Luciano Rossetti will be retiring as global head of R&D for the Healthcare business sector.

Dr Rossetti will be succeeded by Dr Danny Bar-Zohar, who will join the organization on November 1, 2020 as the new global head of development for the Healthcare business sector, and Dr Joern-Peter Halle, who will continue to serve as global head of research for the Healthcare business sector. Dr Rossetti will remain with the organization through December 31, 2020.

“Throughout his six-year tenure as global head of R&D, Luciano Rossetti has had a significant impact on our Healthcare organization and on the lives of patients,” said Belén Garijo, vice chairman of the executive board and deputy chief executive of Merck as well as CEO Healthcare, adding: “He has led the R&D organization through a strategic transformation that has delivered multiple tangible regulatory successes and most importantly, built a durable foundation for the future of scientific and medical innovation at Merck.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK